Halozyme Therapeutics' ENHANZE technology is being utilized by major pharmaceutical companies including AbbVie, Roche, and Lilly.
5 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Halozyme Therapeutics' ENHANZE technology is being utilized by major pharmaceutical companies including AbbVie, Roche, and Lilly.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Halozyme's ENHANZE technology is licensed and used by AbbVie, Roche, and Lilly.1 source
- Halozyme expanded its licensing of ENHANZE technology to Janssen, Pfizer, and other major pharma companies.
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Halozyme Therapeutics
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Coverage
Newest first; wire copies grouped- ZacksHere's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today How much a stock's price changes over time is a significant driver for most investors. Not only can
- PR NewswireHalozyme to Participate at Upcoming Investor Conferences SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, Presid
- PR NewswireHalozyme to Report Second Quarter 2025 Financial and Operating Results SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release
- Unknown outlet
- Unknown outlet